TORONTO, Jan. 6, 2014 /CNW/ - Microbix Biosystems Inc. (TSX: MBX)
("Microbix" or the "Company"), an innovator of biological products and
technologies, announced today it has commenced a patent litigation
against Novartis Vaccines and Diagnostics, headquartered in Basel,
Switzerland, alleging infringement of its proprietary VIRUSMAX
technology. The complaint was filed in the Eastern District of Texas.
Microbix was granted patents for the VIRUSMAX technology in twenty-one
countries between 2006 and 2011.
The Company's VIRUSMAX technology is useful for increasing virus yields
in egg-based vaccine manufacture. The patent application was first
published internationally in 2004 when the global market for influenza
vaccine was US $1.6 billion. At that time, governments, the WHO and
public health authorities worldwide expressed growing concern about
limited global vaccine manufacturing capacity and supply, especially in
light of a potential influenza pandemic.
The influenza vaccine market has experienced significant growth in the
past ten years and is predicted to reach US $4 Billion in 2014. An
independent study published in the Journal of Vaccine in 2006 reported
that the application of VIRUSMAX technology led to a significant
increase in flu virus production in eggs. These trials used methods
comparable to those employed in seasonal influenza vaccine manufacture.
The Company has also demonstrated substantial yield increases over
conventional manufacturing processes for a number of influenza vaccine
strains using its technology.
Vaughn Embro-Pantalony, President and Chief Executive Officer said,
"VIRUSMAX is a novel technology that was developed by our Company at
significant cost. The technology provides significant efficiencies to
the influenza vaccine industry and it benefits the global supply of
vaccine. We intend to enforce our intellectual property rights
surrounding this technology."
About Microbix Biosystems
Microbix Biosystems Inc. specializes in the development of biological
solutions, including products for vaccine and diagnostics markets
worldwide. The company owns intellectual property for an approved
biological drug, a vaccine technology and an animal reproduction
technology. Established in 1988, Microbix is headquartered in Toronto.
Microbix' pipeline of innovative technologies and products includes
LumiSort® semen sexing technology for the livestock industries, and
Kinlytic®, a thrombolytic drug with several approved and potential
applications including the treatment of life-threatening blood clots,
and VIRUSMAX®, a proprietary technology for increasing virus yields in
influenza vaccine manufacture.
This press release may contain forward-looking statements which are
subject to risks and uncertainties that could cause actual results to
differ materially from those set forth in the forward-looking
statements including the risks associated with litigation, operations
in foreign jurisdictions, foreign currency and exchange rate risk, and
risks of raising capital on acceptable terms or at all. These
statements reflect management's current estimates, beliefs, intentions
and expectations; they are not guarantees of future performance. The
Company cautions that all forward-looking information is inherently
uncertain and the actual performance may be affected by a number of
material factors, many of which are beyond the Company's control.
Accordingly, actual future events, conditions and results may differ
materially from the estimates, beliefs, intentions and expectations
expressed or implied in the forward-looking information. All
statements are made as of the date of this news release. The Company
is under no obligation to update or alter any forward-looking
Please visit www.sedar.com for recent Microbix Biosystems Inc. filings on its pipeline products
and financial information.
SOURCE: Microbix Biosystems Inc.
For further information:
Visit www.microbix.com or contact: Vaughn C. Embro-Pantalony, CEO, (905) 361-8910 (ext. 350) or Charles Wallace, CFO, (905) 361-8910 (ext. 255).